Abstract
Breast cancer is a major cause of female death, and various big data analysis methods have been applied to breast cancer. This study lists cases in which big data analysis was applied to breast cancer research. In addition, statistics and percentages from each specific sample were proposed. However, research on the use of big data has a blind spot that relies on sample characteristics. Therefore, before sampling big data, statistical inference should be discussed more precisely through pre-examination and sample statistical errors should be reduced by professional statistical evaluation of the analysis method. In particular, the control and experimental groups should be statistically equivalent.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It is not related to clinical trials because it is mainly an open public data study.
Funding Statement
This work has partially supported by the National Research Foundation of Korea (NRF) grant founded by the Korea government (MSIT) (NRF-2019R1F1A1058771).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of them are open access data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The introduction was supplemented. Figure 1. Figures and tables were divided. Figure 2. The number of overlapping patients is indicated. Table 1, 2 added. Table 1 number 1->3 changed. The role of each gene was inferred by looking at the results. Important points in the results are listed in the contents of the thesis.
Data Availability
I checked the contents related to this.
